Ondine Biomedical Future Growth
Future criteria checks 2/6
Ondine Biomedical's earnings are forecast to decline at 14.6% per annum while its annual revenue is expected to grow at 57.9% per year. EPS is expected to grow by 27% per annum.
Key information
-14.6%
Earnings growth rate
27.0%
EPS growth rate
Medical Equipment earnings growth | 21.5% |
Revenue growth rate | 57.9% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 24 Apr 2024 |
Recent future growth updates
No updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 9 | -28 | N/A | -23 | 1 |
12/31/2025 | 3 | -24 | N/A | -19 | 1 |
12/31/2024 | 3 | -19 | -27 | -16 | 2 |
12/31/2023 | 1 | -16 | -16 | -15 | 2 |
6/30/2023 | 1 | -19 | -16 | -16 | N/A |
3/31/2023 | 1 | -19 | -16 | -16 | N/A |
12/31/2022 | 1 | -19 | -17 | -16 | N/A |
9/30/2022 | 1 | -37 | -18 | -18 | N/A |
6/30/2022 | 1 | -54 | -19 | -19 | N/A |
3/31/2022 | 2 | -52 | -16 | -16 | N/A |
12/31/2021 | 3 | -50 | -13 | -13 | N/A |
12/31/2020 | 2 | -16 | -6 | -6 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: OBI is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: OBI is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: OBI is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: OBI's revenue (57.9% per year) is forecast to grow faster than the UK market (3.3% per year).
High Growth Revenue: OBI's revenue (57.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if OBI's Return on Equity is forecast to be high in 3 years time